In Recognition of Lung Cancer Awareness Month

Best Practices in Lung Cancer – November 2017 Vol 8 —November 15, 2017
Lillie D. Shockney, RN, BS, MAS, ONN-CG
Program Director and Co-Founder, AONN+; University Distinguished Service Professor of Breast Cancer, Departments of Surgery and Oncology; Administrative Director, The Johns Hopkins Breast Center; Director, Cancer Survivorship Programs at the Sidney Kimmel Cancer Center at Johns Hopkins; Professor, JHU School of Medicine, Departments of Surgery, Oncology, Gynecology & Obstetrics - Baltimore, MD

Dear Navigators,

The principles of navigation began in the discipline of breast cancer. After observing the tremendous success of removing barriers to care as an effective method to improve clinical outcome and patient satisfaction, navigation tactics have been incorporated into many oncology disciplines. In this Special Edition, we direct our attention to lung cancer and the positive impact navigators have had in this disease state.

Lung cancer is a field in which great strides have been made over the past decade. From smoking cessation programs to the introduction of immunotherapy to the development and implementation of lung nodule screening, patients living with lung cancer have more treatment options and lifestyle-enhancing services available to them than ever before.

In this issue, we present an interview with Wendy Brooks, RN, ONN-CG(T), a thoracic nurse navigator at the HCA Midwest Research Medical Center, about her typical, or not so typical, day as a navigator. We are pleased to present an article by Amy M. Norton, RN, MSN, ONN-CG(T), and colleagues entitled “Lung Cancer. Now What? Plans and How We ‘Navigate’ Them.” We also bring you news in lung cancer from the European Society for Medical Oncology 2017 Congress.

It is our hope that this issue is a valuable resource to the nurse and patient navigators who work tirelessly to help their patients living with lung cancer. Thank you for all you do for your patients and for your valued and loyal readership.

Sincerely,

Lillie D. Shockney, RN, BS, MAS, ONN-CG
Editor-in-Chief, JONS; Program Director, AONN+

University Distinguished Service Professor of Breast Cancer; Administrative Director, the Johns Hopkins Breast Center; Director, Cancer Survivorship Programs at the Sidney Kimmel Cancer Center at Johns Hopkins; Professor, JHU School of Medicine, Depts of Surgery and Oncology; Cofounder, Johns Hopkins Medicine Managing Cancer at Work.
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Related Articles
AONN+ Metrics Supported by National Oncology Standards
Lillie D. Shockney, RN, BS, MAS, ONN-CG
|
June 2018 Vol 9, No 6
Having a universal tool to measure patient experience, clinical outcome, and return on investment is critical to ensuring the success not only of navigation programs but oncology programs at large.
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Lisa A. Raedler, PhD, RPh
|
2018 Third Annual Oncology Guide to New FDA Approvals
On April 28, 2017, the FDA accelerated the approval of brigatinib (Alunbrig; Takeda Oncology), a new-generation oral ALK inhibitor, for the treatment of patients with ALK-positive metastatic NSCLC who do not tolerate or have had an inadequate response to crizotinib.
Genetic Testing Being Mainstreamed to Consumers—Good or Bad Idea?
Lillie D. Shockney, RN, BS, MAS, ONN-CG
|
May 2018 Vol 9, No 5
JONS Editor in Chief, Lillie Shockney, RN, BS, MAS, ONN-CG, offers her insights on the timely topic of commercially available genetic testing.
Last modified: June 9, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code